Page last updated: 2024-11-04

sulfadiazine and Dysphagia

sulfadiazine has been researched along with Dysphagia in 2 studies

Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.
diazine : The parent structure of the diazines.

Research Excerpts

ExcerptRelevanceReference
"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are infrequent mucocutaneous diseases, rapidly progressive and life-threatening."1.72Odynophagia as the first manifestation of toxic epidermal necrolysis. ( Guallart Domenech, F; Martínez Ruiz de Apodaca, P; Ortega Beltrá, N; Pons Rocher, F, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Ortega Beltrá, N3
Guallart Domenech, F3
Martínez Ruiz de Apodaca, P3
Pons Rocher, F3
Holtkamp, M1
Okuducu, AF1
Klingebiel, R1
Ploner, CJ1

Other Studies

2 other studies available for sulfadiazine and Dysphagia

ArticleYear
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Odynophagia as the first manifestation of toxic epidermal necrolysis.
    BMJ case reports, 2022, Nov-24, Volume: 15, Issue:11

    Topics: Acute Disease; Deglutition Disorders; Humans; Male; Pain; Stevens-Johnson Syndrome; Sulfadiazine

2022
Cerebral toxoplasmosis in a patient with common variable immunodeficiency.
    Neurology, 2004, Dec-14, Volume: 63, Issue:11

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Protozoan; Antiprotozoal Agents; Biopsy; Brain; Central N

2004